RPRX Stock Overview
Operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Royalty Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.22 |
| 52 Week High | US$31.66 |
| 52 Week Low | US$25.10 |
| Beta | 0.47 |
| 11 Month Change | -5.51% |
| 3 Month Change | -5.45% |
| 1 Year Change | -3.53% |
| 33 Year Change | -37.69% |
| 5 Year Change | n/a |
| Change since IPO | -41.08% |
Recent News & Updates
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)
Nov 13
Royalty Pharma: Massive Opportunity Ahead
Nov 09Recent updates
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)
Nov 13Royalty Pharma: Massive Opportunity Ahead
Nov 09Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21
Oct 14Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)
Oct 09Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Aug 22Royalty Pharma: Busy Putting Capital To Work
Aug 11Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21
Jul 22Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Apr 28Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares
Apr 25Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem
Feb 22Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21
Jan 31Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion
Dec 26Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
May 12Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20
Apr 20Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20
Jan 16Royalty Pharma to co-fund development of schizophrenia drug with Merck
Oct 12Shareholder Returns
| RPRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.4% | -5.3% | -1.2% |
| 1Y | -3.5% | 8.7% | 30.4% |
Return vs Industry: RPRX underperformed the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: RPRX underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| RPRX volatility | |
|---|---|
| RPRX Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RPRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RPRX's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Royalty Pharma plc Fundamentals Summary
| RPRX fundamental statistics | |
|---|---|
| Market cap | US$15.32b |
| Earnings (TTM) | US$1.15b |
| Revenue (TTM) | US$2.27b |
10.2x
P/E Ratio5.1x
P/S RatioIs RPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPRX income statement (TTM) | |
|---|---|
| Revenue | US$2.27b |
| Cost of Revenue | US$491.91m |
| Gross Profit | US$1.77b |
| Other Expenses | US$628.98m |
| Earnings | US$1.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.58 |
| Gross Margin | 78.29% |
| Net Profit Margin | 50.53% |
| Debt/Equity Ratio | 74.2% |
How did RPRX perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield32%
Payout RatioDoes RPRX pay a reliable dividends?
See RPRX dividend history and benchmarks| Royalty Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Nov 15 2024 |
| Dividend Pay Date | Dec 10 2024 |
| Days until Ex dividend | 6 days |
| Days until Dividend pay date | 19 days |
Does RPRX pay a reliable dividends?
See RPRX dividend history and benchmarks